- Home
- NPKI vs GHRS Comparison
NPKI vs GHRS Comparison
Compare NPKI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- GHRS
- Stock Information
- Founded
- NPKI 1932
- GHRS 2018
- Country
- NPKI United States
- GHRS Ireland
- Employees
- NPKI N/A
- GHRS N/A
- Industry
- NPKI Metal Fabrications
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- NPKI Industrials
- GHRS Health Care
- Exchange
- NPKI Nasdaq
- GHRS Nasdaq
- Market Cap
- NPKI 881.5M
- GHRS 874.0M
- IPO Year
- NPKI N/A
- GHRS 2021
- Fundamental
- Price
- NPKI $10.67
- GHRS $12.44
- Analyst Decision
- NPKI Strong Buy
- GHRS Strong Buy
- Analyst Count
- NPKI 3
- GHRS 8
- Target Price
- NPKI $12.17
- GHRS $30.63
- AVG Volume (30 Days)
- NPKI 712.0K
- GHRS 183.0K
- Earning Date
- NPKI 11-06-2025
- GHRS 08-07-2025
- Dividend Yield
- NPKI N/A
- GHRS N/A
- EPS Growth
- NPKI N/A
- GHRS N/A
- EPS
- NPKI N/A
- GHRS N/A
- Revenue
- NPKI $234,741,000.00
- GHRS N/A
- Revenue This Year
- NPKI $19.94
- GHRS N/A
- Revenue Next Year
- NPKI $9.36
- GHRS N/A
- P/E Ratio
- NPKI N/A
- GHRS N/A
- Revenue Growth
- NPKI 6.96
- GHRS N/A
- 52 Week Low
- NPKI $4.76
- GHRS $6.00
- 52 Week High
- NPKI $10.75
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- NPKI 70.02
- GHRS 38.34
- Support Level
- NPKI $10.35
- GHRS $12.39
- Resistance Level
- NPKI $10.71
- GHRS $14.59
- Average True Range (ATR)
- NPKI 0.25
- GHRS 0.71
- MACD
- NPKI -0.02
- GHRS -0.08
- Stochastic Oscillator
- NPKI 89.74
- GHRS 2.27
About NPKI NPK International Inc. Common Stock
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.